Very disappointing call. IMO both Kelly and Pourhassan at times were not professional in their responses, especially when the compensation and stock discussion occurred. NP has done a great job getting this molecule to demonstrate efficacy; however, is not able to get it over the finish line with at least one approval. It may be time for all shareholders to think critically about a new leadership team. The FDA will continue to stone wall us at the behest of Gilead. I will be voting NO across the board.